These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21157400)

  • 1. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Nagai G; Kagawa S; Nemoto K; Ohta I; Arakaki H; Uno T; Kondo T
    Ther Drug Monit; 2011 Feb; 33(1):21-4. PubMed ID: 21157400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
    Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.
    Nakamura A; Mihara K; Nemoto K; Nagai G; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2014 Dec; 36(6):815-8. PubMed ID: 24739668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP1A2*F Polymorphism Contributes at Least Partially to the Variability of Plasma Levels of Dehydroaripiprazole, an Active Metabolite of Aripiprazole, in Schizophrenic Patients.
    Suzuki T; Nagai G; Mihara K; Tomori Y; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Drug Metab Bioanal Lett; 2024; 17(1):7-12. PubMed ID: 37855290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
    Nagai G; Mihara K; Nakamura A; Suzuki T; Nemoto K; Kagawa S; Ohta I; Arakaki H; Kondo T
    Psychiatry Clin Neurosci; 2012 Oct; 66(6):518-24. PubMed ID: 23066770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects.
    Kirschbaum KM; Müller MJ; Malevani J; Mobascher A; Burchardt C; Piel M; Hiemke C
    World J Biol Psychiatry; 2008; 9(3):212-8. PubMed ID: 17853280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients.
    Nemoto K; Mihara K; Nakamura A; Nagai G; Kagawa S; Suzuki T; Kondo T
    Pharmacopsychiatry; 2014 May; 47(3):101-4. PubMed ID: 24764200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole.
    Waade RB; Christensen H; Rudberg I; Refsum H; Hermann M
    Ther Drug Monit; 2009 Apr; 31(2):233-8. PubMed ID: 19142178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.
    Hendset M; Hermann M; Lunde H; Refsum H; Molden E
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1147-51. PubMed ID: 17828532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia.
    Bachmann CJ; Rieger-Gies A; Heinzel-Gutenbrunner M; Hiemke C; Remschmidt H; Theisen FM
    Ther Drug Monit; 2008 Aug; 30(4):462-6. PubMed ID: 18641558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of aripiprazole: high serum levels in a CYP2D6 mutated patient.
    Oosterhuis M; Van De Kraats G; Tenback D
    Am J Psychiatry; 2007 Jan; 164(1):175. PubMed ID: 17202571
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.
    Molden E; Lunde H; Lunder N; Refsum H
    Ther Drug Monit; 2006 Dec; 28(6):744-9. PubMed ID: 17164689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia.
    Lin SK; Chen CK; Liu YL
    J Clin Psychopharmacol; 2011 Dec; 31(6):758-62. PubMed ID: 22020350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and quantification of aripiprazole and its metabolite, dehydroaripiprazole, by gas chromatography-mass spectrometry in blood samples of psychiatric patients.
    Huang HC; Liu CH; Lan TH; Hu TM; Chiu HJ; Wu YC; Tseng YL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 856(1-2):57-61. PubMed ID: 17602901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous determination of aripiprazole and its active metabolite, dehydroaripiprazole, in plasma by capillary electrophoresis combining on-column field-amplified sample injection and application in schizophrenia.
    Hwang PL; Wei SY; Yeh HH; Ko JY; Chang CC; Chen SH
    Electrophoresis; 2010 Aug; 31(16):2778-86. PubMed ID: 20665528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Nemoto K; Mihara K; Nakamura A; Nagai G; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2012 Apr; 34(2):188-92. PubMed ID: 22377745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
    Kim JR; Seo HB; Cho JY; Kang DH; Kim YK; Bahk WM; Yu KS; Shin SG; Kwon JS; Jang IJ
    Br J Clin Pharmacol; 2008 Dec; 66(6):802-10. PubMed ID: 19032724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.
    Kubo M; Koue T; Maune H; Fukuda T; Azuma J
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):358-66. PubMed ID: 17965519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1.
    Nagai G; Mihara K; Nakamura A; Nemoto K; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2017 Feb; 39(1):62-65. PubMed ID: 27861318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
    Mihara K; Suzuki A; Kondo T; Yasui N; Furukori H; Nagashima U; Otani K; Kaneko S; Inoue Y
    Clin Pharmacol Ther; 1999 Mar; 65(3):291-4. PubMed ID: 10096261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.